MetaVia announces successful dose titration completion for DA-1726
All active patients in MetaVia's Phase 1 Part 3 obesity study reached target doses, indicating favorable tolerability for DA-1726. The company projects no delays to its Q4 2026 top-line data timeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day